Loading clinical trials...

Ketamine Trial for the Treatment of Depression | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Ketamine Trial for the Treatment of Depression

Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase

NCT02401139•The University of New South Wales

View on ClinicalTrials.gov

Summary

This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.

Eligibility

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals will be eligible for enrolment on the basis of:
•major depressive disorder for at least three months duration
•an inadequate response to at least 2 adequate antidepressants
•MADRS ≥ 20
•Patients will be excluded on the basis of:
•History of psychosis
•History of bipolar disorder
•Any unstable medical or neurologic condition
•Any Axis I disorder other than MDD judged to be primary presenting problem
•Planned major changes to psychotropic medication
+10 more criteria

Locations (2)

Brain & Mind Research Institute (BMRI), University of Sydney

Camperdown, New South Wales, Australia

Black Dog Institute, University of New South Wales

Sydney, New South Wales, Australia

Key Dates

Start Date

March 1, 2015

Primary Completion Date

July 1, 2015

Completion Date

September 1, 2015

Last Updated

March 30, 2023

Enrollment

ACTUAL participants

Conditions

Unipolar Depression

Interventions

Ketamine

DRUG

Placebo

DRUG

Transcranial Direct Current Stimulation for Depression

NCT07042217

Unipolar Depression

View study

RECRUITINGNA

Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression

NCT06371352

Unipolar DepressionBipolar Disorder

View study

RECRUITINGNA

How to Reduce Suicidal Thoughts and Impulsivity in Depression

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 30, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ketamine Trial for the Treatment of Depression

Inclusion Criteria

Transcranial Direct Current Stimulation for Depression

Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression

How to Reduce Suicidal Thoughts and Impulsivity in Depression

Sensor-based Characterization of Depression

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies